ANJARIUM BIOSCIENCES
Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic diseases throughout a patient's lifetime. Combining deep domain expertise in synthetic and natural delivery systems, Anjarium is developing a novel class of bioinspired nanomedicine to address a range of genetic diseases, including those that necessitate very large gene delivery. Anjarium’s versatile platform systematically addresses key deficiencies of viral gene therapies in order to provide benefits to patients that have previously been out of reach.
ANJARIUM BIOSCIENCES
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.anjarium.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
55.5 M CHF
Technology used in webpage:
Viewport Meta Google Font API Google Tag Manager Google Analytics Google Maps Content Delivery Network Amazon Global Site Tag HSTS Organization Schema
Similar Organizations
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
ARTHEx Biotech
AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.
BerGenBio
BerGenBio is clinical-stage biopharma developing first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
GlycoEra
GlycoEra is a CustomGlycanengineering platform that unlocks the glycan-mediated biology to develop a pipeline of novel therapeutics.
Imcyse
Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors.
New Amsterdam Pharma
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
Ribbon Biolabs
Ribbon Biolabs defines new standards for molecular biology by applying innovative methods for DNA synthesis.
Current Advisors List
Current Employees Featured
Founder
Investors List
Omega Funds
Omega Funds investment in Series A - Anjarium Biosciences
Abingworth
Abingworth investment in Series A - Anjarium Biosciences
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - Anjarium Biosciences
Gimv
Gimv investment in Series A - Anjarium Biosciences
Surveyor Capital
Surveyor Capital investment in Series A - Anjarium Biosciences
Swiss Federal Commission for Innovation and Technology
Swiss Federal Commission for Innovation and Technology investment in Grant - Anjarium Biosciences
Key Employee Changes
Official Site Inspections
http://www.anjarium.com Semrush global rank: 9.99 M Semrush visits lastest month: 286
- Host name: 199.60.103.174
- IP address: 199.60.103.174
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "Anjarium Biosciences"
Anjarium Biosciences - Crunchbase Company Profile & Funding
Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic diseases throughout a patient's …See details»
Anjarium Biosciences Company Profile 2024: Valuation, Funding ...
Anjarium Biosciences is headquartered in Schlieren, Switzerland. What is the size of Anjarium Biosciences? Anjarium Biosciences has 39 total employees. What industry is Anjarium …See details»
Anjarium Biosciences AG - Swiss Biotech
Anjarium Biosciences AG is a genetic medicines company focused on creating and delivering a new generation of targeted gene therapies to patients. Anjarium’s versatile platform builds on …See details»
Anjarium Biosciences - Contacts, Employees, Board Members
Organization. Anjarium Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Anjarium Biosciences has 5 current employee profiles, …See details»
Anjarium Biosciences AG - VentureRadar
Anjarium is developing a new generation of genetic medicines to overcome the greatest challenges facing the field, notably immunogenicity, payload capacity, individualized multiple …See details»
Anjarium Biosciences - Funding, Financials, Valuation & Investors
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases. ... How much funding has this organization …See details»
Anjarium Biosciences appoints Stephen Yoo, MD as Chief …
SCHLIEREN, ZURICH, June 14, 2022 — Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today …See details»
Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing …
Sep 16, 2021 SCHLIEREN, ZURICH, September 16, 2021 — Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral …See details»
Anjarium Biosciences appoints Stephen Yoo, MD as Chief …
Jun 14, 2022 Anjarium's versatile technology shows exciting potential in multiple disease areas, and I'm thrilled to be joining a company at the cutting-edge of this science as it grows its …See details»
Abingworth, Gimv and Pfizer back stealthy Swiss startup's $61M …
Sep 16, 2021 After working quietly for several years to realize the vision, de Beer’s Anjarium Biosciences has now broken cover with 55.5 million Swiss francs ($61 million) from top-tier …See details»
Anjarium Biosciences’ CEO on its next-gen gene therapies
Jul 15, 2022 Among those generating buzz is Switzerland-based Anjarium Biosciences, who crowned Stephen Yoo as its new CEO in June. Drawing on his medical training and extensive …See details»
Anjarium: a hybrid approach to non-viral gene therapy
Sep 16, 2021 Switzerland-based Anjarium believes its platform using lipid nanoparticles and extracellular vesicles can help create non-viral gene therapies that can find a niche in the …See details»
Anjarium Biosciences appoints experienced industry executives …
Jul 12, 2022 Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announces the expansion of its …See details»
Anjarium Biosciences raises CHF 55.5M to develop non-viral gene ...
Sep 16, 2021 Anjarium Biosciences AG ("Anjarium"), a biotech company focused on creating and delivering a new class of non-viral gene therapies today announced the closing of a …See details»
Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing …
ZURICH, Sept. 16, 2021 /PRNewswire/ -- Anjarium Biosciences AG ("Anjarium"), a biotech company focused on creating and delivering a new class of non-viral gene therapies today …See details»
Anjarium Raises $61 Million to Develop Next-Generation Non-viral …
Sep 16, 2021 Anjarium Raises $61 Million to Develop Next-Generation Non-viral Gene Therapies September 16, 2021 Swiss biotech Anjarium Biosciences raised $61 million …See details»
Anjarium Biosciences Appoints Gaurav Shah as Chairperson and …
Oct 18, 2022 Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announces the expansion of its …See details»
ANJARIUM BIOSCIENCES PRESENTS DATA DEMONSTRATING …
May 7, 2024 Anjarium Biosciences, a cell and gene therapy tools and technology company enabling researchers and manufacturers to accelerate the discovery and delivery cycle of new …See details»
Anjarium Biosciences Presents Data Demonstrating Novel …
May 7, 2024 Anjarium Biosciences, a cell and gene therapy tools and technology company enabling researchers and manufacturers to accelerate the discovery and delivery cycle of new …See details»